Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib Add-on in ImmunoMetabolic Depression
NCT05415397Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of celecoxib oral solution in major depressive disorder (MDD), sponsored by Amsterdam University Medical Center. Started Sep 2022; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05415397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05415397.